Beacon Biosignals Raises $27 Million Series A Led By General Catalyst To Scale Its Eeg Neurobiomarker Discovery Platform

Nov 08, 2021•about 4 years ago

Amount Raised

$27 Million

Round Type

series a

Boston

Description

Beacon Biosignals, a neurotechnology company applying artificial intelligence to EEG (electroencephalography) to unlock precision medicine for any condition affecting the brain, has announced an oversubscribed $27M Series A financing led by General Catalyst and with participation from Casdin Capital. Proceeds will be used to scale Beacon's computational biomarker discovery platform and address the massive unmet need for quantitative clinical trial endpoints, safety tools, and computational diagnostics for neurology, psychiatry, and sleep medicine.

Company Information

Company

Beacon Biosignals

Location

Boston, Massachusetts, United States

About

Beacon's machine learning platform for EEG enables and accelerates new treatments that transform the lives of patients with neurological, psychiatric or sleep disorders. Through novel machine learning algorithms, large datasets, and advances in software engineering, Beacon Biosignals is changing the way patients are treated for disorders of the brain. For more information, visit https://beacon.bio/. For careers, visit https://beacon.bio/careers; for partnership inquiries, visit https://beacon.bio/contact. Follow us on Twitter (@Biosignals) or LinkedIn (https://www.linkedin.com/company/beacon-biosignals).

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Beacon Biosignals Raises $27 Million Series A Led By General Catalyst To Scale Its Eeg Neurobiomarker Discovery Platform

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information